T. Rowe Price Associates’s Royalty Pharma RPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $9.99M | Buy |
277,189
+7,726
| +3% | +$278K | ﹤0.01% | 1113 |
|
|
2025
Q1 | $8.39M | Buy |
269,463
+23,016
| +9% | +$717K | ﹤0.01% | 1146 |
|
|
2024
Q4 | $6.29M | Sell |
246,447
-39,852
| -14% | -$1.02M | ﹤0.01% | 1227 |
|
|
2024
Q3 | $8.1M | Buy |
286,299
+15,847
| +6% | +$448K | ﹤0.01% | 1179 |
|
|
2024
Q2 | $7.13M | Buy |
270,452
+8,722
| +3% | +$230K | ﹤0.01% | 1161 |
|
|
2024
Q1 | $7.95M | Sell |
261,730
-1,106,424
| -81% | -$33.6M | ﹤0.01% | 1144 |
|
|
2023
Q4 | $38.4M | Sell |
1,368,154
-622,848
| -31% | -$17.5M | 0.01% | 775 |
|
|
2023
Q3 | $54M | Sell |
1,991,002
-303,414
| -13% | -$8.23M | 0.01% | 658 |
|
|
2023
Q2 | $70.5M | Sell |
2,294,416
-181,531
| -7% | -$5.58M | 0.01% | 605 |
|
|
2023
Q1 | $89.2M | Sell |
2,475,947
-28,585
| -1% | -$1.03M | 0.01% | 535 |
|
|
2022
Q4 | $99M | Buy |
2,504,532
+161,722
| +7% | +$6.39M | 0.02% | 498 |
|
|
2022
Q3 | $94.1M | Sell |
2,342,810
-9,732
| -0.4% | -$391K | 0.02% | 499 |
|
|
2022
Q2 | $98.9M | Buy |
2,352,542
+91,343
| +4% | +$3.84M | 0.01% | 665 |
|
|
2022
Q1 | $88.1M | Sell |
2,261,199
-16,360
| -0.7% | -$637K | 0.01% | 769 |
|
|
2021
Q4 | $90.8M | Buy |
2,277,559
+80,823
| +4% | +$3.22M | 0.01% | 795 |
|
|
2021
Q3 | $79.4M | Sell |
2,196,736
-3,117
| -0.1% | -$113K | 0.01% | 842 |
|
|
2021
Q2 | $90.2M | Sell |
2,199,853
-154,365
| -7% | -$6.33M | 0.01% | 815 |
|
|
2021
Q1 | $103M | Sell |
2,354,218
-854,937
| -27% | -$37.3M | 0.01% | 767 |
|
|
2020
Q4 | $161M | Sell |
3,209,155
-5,021,895
| -61% | -$251M | 0.02% | 581 |
|
|
2020
Q3 | $346M | Buy |
8,231,050
+208,579
| +3% | +$8.77M | 0.04% | 362 |
|
|
2020
Q2 | $389M | Buy |
+8,022,471
| New | +$389M | 0.05% | 333 |
|